硫胺是通过抑制VEGFR-2进行癌症治疗的有希望的打击
Eleftherios Charissopoulos1, Eleni Pontiki1
1Department of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Biomedicines
|April 29, 2025
概括
新型硫胺衍生物显示为癌症治疗的多向药物,抑制血管内皮生长因子受体-2 (VEGFR-2),并可能克服与当前治疗相关的抗性和副作用.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 血管内皮生长因子受体-2 (VEGFR-2) 是抗血管原性癌症治疗的关键标,因为它在瘤血管生成中的作用.
- 目前的VEGFR-2抑制剂面临的挑战包括药物耐药性和心脏副作用.
- 开发新的治疗策略对于提高疗效和尽量减少不良事件至关重要.
研究的目的:
- 审查具有潜在VEGFR-2抑制活性的新型化合物.
- 探索针对多种途径的多功能药物,以改善癌症治疗.
- 突出硫胺衍生物作为药物发现的有前途的候选人.
主要方法:
- 关于VEGFR-2抑制剂的最近研究的文献综述.
- 专注于具有双重抑制作用的硫胺衍生物.
- 对向VEGFR-2和碳酸无水酶的化合物的分析.
主要成果:
- 识别具有潜在VEGFR-2抑制活性的新型化合物.
- 四种化合物表现出额外的碳酸胺酶抑制活性.
- 硫胺衍生物为开发多目标药物提供了多功能支架.
结论:
- 新型硫胺衍生物代表了开发下一代抗血管性癌症疗法的有希望的途径.
- 针对VEGFR-2和其他途径的多功能药物可以克服耐药性并减少副作用.
- 对这些化合物的进一步研究可能会导致更有效的癌症治疗.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Rous Sarcoma Virus (RSV) and Cancer
4.9K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
4.9K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


